scholarly journals Co-Occurrence of Multiple Sclerosis & Ovarian Cancer: A Case Report and Literature Review

2021 ◽  
pp. 1-4
Author(s):  
Danni XU ◽  
Fengxiang Han ◽  
Caiwei Lu ◽  
Chunxiang Luo ◽  
Xiaohui Liao ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Ovarian Cancer ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Immunomodulatory Drugs ◽  
Node Dissection ◽  
Case Presentation ◽  
Aortic Lymph Node ◽  
Stage Ia ◽  
Carboplatin Auc

Background: The possibility of an association between Multiple Sclerosis (MS) and cancer has not been thoroughly investigated. Case Presentation: We present a case of ovarian cancer in 58-year-old woman with MS. Radical hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and pelvic and para-aortic lymph node dissection was performed. Pathohistological analysis and immunohistochemistry confirmed the diagnosis of a clear cell carcinoma of the left ovary, grade Ⅲ, FIGO2014 stage IA. Adjuvant chemotherapy of paclitaxel-carboplatin regimen (paclitaxel 175mg/m2, carboplatin AUC 6, at intervals of 3 weeks) was implemented for 4 courses. Conclusion: The occurrence of ovarian cancer in MS patients may be coincidental. Nevertheless, the longterm use of immunosuppressive and/or immunomodulatory drugs in MS and the incidence of cancer may be associated.

scholarly journals Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma

2021 ◽  
Author(s):  
Kosuke Murakami ◽  
Akiko Kanto ◽  
Kazuko Sakai ◽  
Chiho Miyagawa ◽  
Hisamitsu Takaya ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Driver Mutations ◽  
Intratumor Heterogeneity ◽  
Ovarian Clear Cell Carcinoma ◽  
Eutopic Endometrium ◽  
Stromal Component ◽  
Hotspot Mutations

AbstractRecent studies have reported cancer-associated mutations in normal endometrium. Mutations in eutopic endometrium may lead to endometriosis and endometriosis-associated ovarian cancer. We investigated PIK3CA mutations (PIK3CAm) for three hotspots (E542K, E545K, H1047R) in eutopic endometrium in patients with ovarian cancer and endometriosis from formalin-fixed paraffin-embedded specimens by laser-capture microdissection and droplet digital PCR. The presence of PIK3CAm in eutopic endometrial glands with mutant allele frequency ≥ 15% were as follows: ovarian clear cell carcinoma (OCCC) with PIK3CAm in tumors, 20/300 hotspots in 11/14 cases; OCCC without PIK3CAm, 42/78 hotspots in 11/12 cases; high-grade serous ovarian carcinoma, 8/45 hotspots in 3/5 cases; and endometriotic cysts, 5/63 hotspots in 5/6 cases. These rates were more frequent than in noncancer nonendometriosis controls (7/309 hotspots in 5/17 cases). In OCCC without PIK3CAm, 7/12 (58%) cases showed multiple hotspot mutations in the same eutopic endometrial glands. In 3/54 (5.6%) cases, PIK3CAm was found in eutopic endometrial stroma. Multisampling of the OCCC tumors with PIK3CAm showed intratumor heterogeneity in three of eight cases. In two cases, PIK3CAm was detected in the stromal component of the tumor. Homogenous PIK3CAm in the epithelial component of the tumor matched the mutation in eutopic endometrial glands in only one case. Eutopic endometrial glands in ovarian cancer and endometriosis show high frequency of PIK3CAm that is not consistent with tumors, and multiple hotspot mutations are often found in the same glands. While the mutations identified in eutopic endometrium may not be driver mutations in the patient’s cancer, these are still driver mutations but this specific clone has not undergone the requisite steps for the development of cancer.

Synchronous primary endometrial and ovarian cancer with three different histologic patterns: A case report

2003 ◽  
Vol 13 (5) ◽  
pp. 678-682 ◽  
Author(s):  
Y.-S. Ree ◽  
S.-H. Cho ◽  
S.-R. Kim ◽  
S.-H. Cho ◽  
K.-T. Kim ◽  
...  
Keyword(s):  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Female Genital Tract ◽  
Figo Stage ◽  
Primary Cancer ◽  
Metastatic Lesions ◽  
Synchronous Cancers ◽  
Stage Ia ◽  
The Right ◽  
Female Genital

Synchronous cancers involving both endometrium and ovary in the female genital tract is a well-recognized phenomenon. However, most of them are metastatic lesions arising from one organ and simultaneous primary cancer occurring in both organs is relatively rare. We report a case with dual primary cancer occurring in both ovaries and endometrium with three different histologies. Recently, a 46-year-old women presented with vaginal bleeding was found to have FIGO stage IC clear cell carcinoma of the left ovary, stage IA borderline mucinous cystadoma of the right ovary, and stage IB endometrial carcinoma of endometrioid type. We present this case with a brief review of references.

scholarly journals Spontaneous arterial thrombosis in a patient with advanced ovarian clear cell cancer: a case report and literature review

2020 ◽  
Vol 48 (6) ◽  
pp. 030006052092674
Author(s):  
Jing Chen ◽  
Huimin Sun ◽  
Minrong Wu ◽  
Xiaolin Zhong ◽  
Yuqin Zhang
Keyword(s):  
Ovarian Cancer ◽  
Venous Thrombosis ◽  
Arterial Thrombosis ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Cell Cancer ◽  
Underlying Disease ◽  
Low Molecular Weight ◽  
Vein Thrombosis ◽  
Deep Vein

Patients with ovarian cancer are often in a hypercoagulable state and have a high risk of venous thrombosis, including deep vein thrombosis and pulmonary embolism. However, arterial thrombosis is relatively rare in ovarian cancer. We report a case a 46-year-old woman with ovarian clear cell carcinoma who developed arterial and venous thrombosis in the lower extremities as the first manifestation. Her arterial thrombosis-related ischemic symptoms were not responsive to anticoagulant treatment of low-molecular-weight heparin, but improved after neoadjuvant chemotherapy and surgery. Therefore, we hypothesize that the optimal therapy for arterial thrombosis in ovarian cancer is treatment for the underlying disease (i.e., ovarian cancer). A thorough investigation is required to determine the relationships between arterial thrombosis and ovarian cancer and antithrombotic treatments for ovarian cancer related-arterial thrombosis.

The role of extensive lymphadenectomy in stage I ovarian cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 5069-5069
Author(s):  
E. G. Munro ◽  
N. Karnik Lee ◽  
M. K. Cheung ◽  
K. Osann ◽  
A. Husain ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Proportional Hazards ◽  
Clear Cell ◽  
Median Number ◽  
Cox Proportional Hazards ◽  
Stage I ◽  
Extensive Lymphadenectomy ◽  
Stage Ib ◽  
Primary Surgery ◽  
Stage Ia

5069 Background: To determine if extent of lymphadenectomy affects the survival of women with stage I ovarian cancer. Methods: Demographic and clinico-pathologic information were obtained from the Surveillance, Epidemiology and End Results Program from 1988–2001 and analyzed using Kaplan-Meier methods and Cox proportional hazards regression. Results: Of the 6,686 women diagnosed with stage I ovarian cancer, 4,092 (61.2%) had stage IA, 392 (5.9%) had stage IB, 1,840 (27.5%) had stage IC, and 362 (5.4%) had unspecified stage I disease. The median age was 53 (range: 1–99). 5,625 (84.1%) were White, 388 (5.8%) Black, 488 (7.3%) Asian, and 185 (2.8%) were Other. All patients underwent primary surgery; of which, 3,824 women had no nodes, 1,533 had <10 nodes, and 1,329 had ≥10 nodes resected. Of the patients who underwent a lymphadenectomy, the median number of nodes resected was 9 (range: 1–84). The extent of lymphadenectomy (0, <10, and ≥10 nodes) increased the survival of patients with stage IC disease from 72.8%, 86.7%, to 90.1% (p < 0.0001), but not in those with stage IA (p = 0.07) or stage IB (p = 0.04) disease. In patients with non-clear cell epithelial carcinoma, the extent of lymphadenectomy was associated with improved 5-year disease-specific survivals of 85.6%, 93.3%, and 93.5%, respectively (p < 0.0001). However, the benefit associated with an extensive lymphadenectomy was not evident in clear cell (p = 0.09), sarcoma (p = 0.33), germ cell (p = 0.55), or sex cord stromal tumors of the ovary (p = 0.99). Similarly, patients with grade 3 disease had an improved survival associated with the extent of lymph node resection, 74.4%, 87.5%, to 90.5% (p < 0.0001), but not in those with grade 1 (p = 0.18) or grade 2 (p = 0.27) disease. In multivariate analysis, a more extensive lymphadenectomy remained significant as an independent prognostic factor for improved survival after adjusting for all other independent prognostic factors including age, surgery, histology, stage, and grade. Conclusions: Our findings suggest that the extent of lymphadenectomy was associated with an improvement in the survival of women with stage IC ovarian cancer. No significant financial relationships to disclose.

An evaluation of survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: A Gynecologic Oncology Group experience.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 5534-5534 ◽  
Author(s):  
John H. Farley ◽  
William E. Brady ◽  
Michael J. Birrer ◽  
David Marc Gershenson ◽  
Gini F. Fleming ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Epithelial Ovarian Cancer ◽  
Cell Carcinoma ◽  
Treatment Effect ◽  
Late Stage ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Early Stage ◽  
Performance Status

5534 Background: We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). Methods: Data from stage I-IV epithelial ovarian cancer (EOC) patients who participated in 12 randomized GOG protocols using platinum-based chemotherapy were reviewed. Proportional hazards models adjusted for age and stratified by protocol, treatment arm, stage, performance status (PS), and race were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). Results: There were 10,803 patients enrolled, 1272 were not eligible: leaving 9,531, of whom 544 (6%) had OCCC, 7,054 (74%) had SOC, and 1,933 (20%) had other; only the OCCC and SOC are considered here. OCCC were significantly younger, more often of Asian race, stage I, good PS, and optimally surgically debulked than SOC patients. Prior to adjustment, OCCC had better PFS and OS due to better prognostic factors. There was no significant difference in PFS or OS for early stage OCCC patients compared to high-grade (HG) SOC patients. For late stage patients, OCCC had poorer PFS and OS compared to SOC, OS HR= 1.66 (1.43, 1.91; p < 0.001). For both optimal, HR = 1.34 (1.10, 1.63; p = 0.003) and suboptimal, HR = 3.18 (2.13, 4.75; p < 0.001) OCCC had a significantly poorer OS than SOC. After adjusting for age and stratified by protocol and treatment arm, stage, performance status, and race, OCCC had a significantly decreased OS, HR= 1.53 (1.33,1.76; p < 0.001). In early stage cases, there was a significantly decreased treatment effect on PFS for consolidative therapy with weekly taxol versus observation in SOC compared to OCCC (p = 0.048). Conclusions: This is one of the largest analyses to date of OCCC treated in a uniform manner . OCCC patients have better PFS and OS compared to SOC; this, is due to their better prognostic factors. There was no observed difference in PFS or OS for early stage OCCC versus HGSOC. In late-stage patients, OCCC was significantly associated with decreased OS which was true for both optimal and suboptimally debulked patients. Finally, treatment effect was influenced by histology.

Clinical characteristics of clear cell ovarian cancer: A retrospective multicenter experience of 308 patients in South Korea.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17062-e17062
Author(s):  
Hee Yeon Lee ◽  
Ji Hyung Hong ◽  
Jae Ho Byun ◽  
Hee Jun Kim ◽  
Sun Kyung Baek ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Adjuvant Chemotherapy ◽  
South Korea ◽  
Clear Cell ◽  
Early Stage ◽  
Stage Iv ◽  
Stage Iii ◽  
Stage Ia ◽  
Optimal Debulking ◽  
Disease Free

e17062 Background: Clear cell ovarian cancer is rare, accounts for about 3-10% of epithelial ovarian carcinoma, and is known to be associated with endometriosis. This tumor type has poor prognosis due to inherent chemoresistance. We investigated clinical characteristics and prognostic factors of clear cell ovarian cancer in South Korea. Methods: We reviewed the medical records of 308 patients with clear cell histology ovarian cancer who underwent debulking surgery from 21 institutions in South Korea between 1995 and 2015. Results: Mean age was 51 years (range, 25-81) and 194 patients (63.7%) had stage I disease, 34 (11.1%) had stage II, 66 (21.6%) had stage III, and 11 (3.6%) had stage IV. 107 patients (34.9%) had endometriosis. 9 patients (2.9%) received neoadjuvant chemotherapy, 248 (80.5%) received postoperative chemotherapy, and among them, 238 (96%) received taxane-platinum chemotherapy. 275 patients (89.3%) achieved optimal debulking. 112 patients (37%) had recurrence, 182 (59.1%) was disease-free, and 12 (3.9%) lost follow up. Median value of CA-125 was 72.34 U/ml (range, 1.9-8930), 45.7 in stage I, 98.9 in stage II, 192.1 in stage III, and 634.8 in stage IV. 1-year, and 3-year rate of disease-free survival (DFS) was 70%, and 63%, respectively. 1-yr DFS rate was 90% in stage Ia and Ib, 88% in stage Ic and II, and 60% in stage III and IV. According to the same stage grouping, 3-year DFS rate was 82%, 70%, and 40%, respectively. Overall survival (OS) rate at 1 year was 97%, 99%, and 90%, and 97%, 96%, and 88% at 3 year. Multivariate analysis revealed optimal debulking (HR 6.62, p < 0.001) as a significant prognostic factor for DFS. Among the 94 patients with early stage (Ia and Ib), 17 patients (18.1%) received adjuvant chemotherapy, and there was no significant difference in DFS according to adjuvant chemotherapy (log rank p = 0.57). Conclusions: In patients with clear cell ovarian cancer, optimal debulking surgery was associated with improved DFS. And the role of adjuvant chemotherapy in early stage clear cell ovarian cancer is elusive and needs further study.

Differences in LINE-1 Methylation Between Endometriotic Ovarian Cyst and Endometriosis-Associated Ovarian Cancer

2014 ◽  
Vol 24 (1) ◽  
pp. 36-42 ◽  
Author(s):  
Ajaree Senthong ◽  
Nakarin Kitkumthorn ◽  
Prakasit Rattanatanyong ◽  
Nipon Khemapech ◽  
Surang Triratanachart ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Progression ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Methylation Status ◽  
Endometrioid Adenocarcinoma ◽  
First Line ◽  
Normal Endometrium ◽  
Eutopic Endometrium ◽  
Long Interspersed Element

BackgroundEndometriosis in endometriosis-associated ovarian cancer (EAOC) refers to lesions that can derive from endometriotic ovarian cysts (ECs) that form in the ovarian endometrium with the potential to transform into full-blown ovarian cancer. Hypomethylation of long interspersed element-1 (LINE-1 or L1) is a common epigenomic event in several cancers and is strongly associated with ovarian cancer progression.ObjectivesTo evaluated alterations in LINE-1 methylation between EC, ovarian endometrioid adenocarcinoma (OEA), EAOC, and ovarian clear cell carcinoma (OCC).Methods/ MaterialsFirst, LINE-1 methylation status in 19 normal endometrium, 29 EC, 35 OCC, and 22 OEA tissues from unrelated samples were compared. Then, specific areas of eutopic endometrium, contiguous endometriosis, and cancer arising from 16 EAOCs were collected by microdissection and analyzed for LINE-1 methylation status.ResultsThe total LINE-1 methylation levels were significantly different among the endometrium, endometriosis, and ovarian cancer (P < 0.001). A stepwise decrease in LINE-1 methylation was observed in the following order: normal endometrium, EC, OEA, and OCC. Interestingly, endometriosis in EAOC of both OEA (P = 0.016) and OCC (P = 0.003) possessed a higher percentage of LINE-1 unmethylated loci than EC.ConclusionOur data implicate that LINE-1 hypomethylation is an early molecular event involved in OEA and OCC malignant transformation. Precise measurements of LINE-1 methylation may help to distinguish EC and endometriosis in EAOC.

Sign in / Sign up

Export Citation Format

Share Document